Braeburn raises $110m for opioid use disorder depot injection

Braeburn Pharmaceuticals has raised $110 million in a mezzanine round of financing led by Wellington Capital. Other investors included Avista Capital Parnters, RA Capital Management, Deerfield Management and Apple Tree Partners. The Princeton, N.J.-based company said it plans to use the new funds to support the FDA approval process and commercialization of CAM2038, a weekly and monthly buprenorphine depot injection designed to treat adults with opioid use disorder. Get the full story at our sister site, Drug Delivery Business News. The post Braeburn raises $110m for opioid use disorder depot injection appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Funding Roundup Pain Management Pharmaceuticals Braeburn Pharmaceuticals Source Type: news